Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix

详细信息    查看全文

• 作者：M. Frumovitz^a ; ^{mfrumovitz@mdanderson.org} ; M.F. Munsell^b ; J.K. Burzawa^a ; L.A. Byers^c ; P. Ramalingam^d ; J. Brown^e ; R.L. Coleman^a
• 关键词：Cervical cancer ; Small cell carcinoma ; Neuroendocrine
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：46-50
• 全文大小：286 K
• 卷排序：144

文摘

Topotecan, paclitaxel, and bevacizumab improve PFS in small cell cervical cancer. The regimen showed a trend towards improved overall survival. Complete responses were achieved in multiple women with recurrent disease.